Gene editing therapy companies rise on word of streamlined...

2025-10-31 12:14:01 ET More on CRISPR Therapeutics Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook Crispr: Investors Waiting Patiently For In-Vivo Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On Track CRISPR Therapeutics files for $600M stock offering Cathie Wood's Ark Invest weekly recap: lifts stake in Bullish and Brera, trims Roku and Tempus AI Read the full article on Seeking Alpha For further details see: Gene editing therapy companies rise on word of streamlined FDA approval process